These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 633083)

  • 1. Studies with a new antifolate 2,4-diamino-5-adamantyl-6-methylpyrimidine (DAMP): tissue distribution and disposition of 2,4-diamino-5-adamantyl-6-methylpyrimidine and its metabolite.
    Zakrzewski SF; Dave C; Mead LH; Deluomo DS
    J Pharmacol Exp Ther; 1978 Apr; 205(1):19-26. PubMed ID: 633083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogs.
    Zakrzewski SF; Pavelic Z; Greco WR; Bullard G; Creaven PJ; Mihich E
    Cancer Res; 1982 Jun; 42(6):2177-83. PubMed ID: 7074598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antitumor activity and toxicity of 2,4-diamino-5-(1-adamantyl)-6-methylpyrimidine and 2,4-diamino-5-(1-adamantyl)-6-ethylpyrimidine.
    Zakrzewski SF; Dave C; Rosen F
    J Natl Cancer Inst; 1978 May; 60(5):1029-33. PubMed ID: 580441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer graphic modeling in drug design--conformational analysis of antifolate binding to avian dihydrofolate reductase: crystal and molecular structures of 2,4-diamino-5-cyclohexyl-6-methylpyrimidine and 5-cyclohexyl-6-methyluracil.
    Cody V; Ciszak E
    Anticancer Drug Des; 1991 May; 6(2):83-93. PubMed ID: 2039584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The disposition and metabolism of [14C]piritrexim in rats after intravenous and oral administration.
    Woolley JL; Deangelis DV; Crouch RC; Shockcor JP; Sigel CW
    Drug Metab Dispos; 1991; 19(3):600-8. PubMed ID: 1680625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate.
    Creaven PJ; Zakrzewski SF; Greco WR; Madajewicz S; Mittelman A; Pontes JE; Karakousis C; Takita H; Proefrock A
    Cancer Chemother Pharmacol; 1988; 21(2):122-8. PubMed ID: 2832091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNDO/2 molecular orbital calculations on the antifolate DAMP and some related species: structural geometries, ring distortions, change distributions and conformational characteristics.
    Welsh WJ; Cody V; Mark JE; Zakrzewski SF
    Cancer Biochem Biophys; 1983 Dec; 7(1):27-38. PubMed ID: 6667452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular structures of 2,4-diaminopyrimidine antifolates with antineoplastic activity.
    Cody V; Zakrzewski SF
    J Med Chem; 1982 Apr; 25(4):427-30. PubMed ID: 7069721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tissue distribution of 14C-tetroxoprim in the rat (author's transl)].
    Vergin H
    Arzneimittelforschung; 1980; 30(2):309-13. PubMed ID: 7378110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
    Pestieau SR; Stuart OA; Sugarbaker PH
    Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog.
    Wong BK; Woolf TF; Chang T; Whitfield LR
    Drug Metab Dispos; 1990; 18(6):980-6. PubMed ID: 1981548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
    Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of hemantane in rats].
    Litvin EA; Bastrygin DV; Kolyvanov GB; Alekseev KV; Zherdev VP
    Eksp Klin Farmakol; 2011; 74(11):24-8. PubMed ID: 22288156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic reduction of 1-nitrosoadamantane by rabbit liver microsomes. Properties of a C-nitroso reductase system.
    Bélanger PM; Grech-Bélanger O
    Drug Metab Dispos; 1979; 7(3):171-5. PubMed ID: 38089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic study of 2-(N-benzylamino)adamatane (bemantan) by a gas-liquid chromatographic method].
    Liubimov BI; Skoldinov AP; Boĭko SS; Rodionov AP; Mozhaeva TIa
    Farmakol Toksikol; 1980; 43(4):408-11. PubMed ID: 7439377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 2nd communication: tissue distributions, placental transfer and milk secretion of radioactivity after a single intravenous 14C-NS-7 injection to rats.
    Nonaka K; Tsujioka T; Tougou K; Mukai H
    Arzneimittelforschung; 2003; 53(10):695-700. PubMed ID: 14650361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and disposition of 3-amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene in the rat.
    Basseches PJ; Powis G
    Cancer Res; 1984 Sep; 44(9):3672-8. PubMed ID: 6540141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-(1-Adamantyl) pyrimidines as inhibitors of folate metabolism.
    Ho YK; Hakala MT; Zakrzewski SF
    Cancer Res; 1972 May; 32(5):1023-8. PubMed ID: 4552913
    [No Abstract]   [Full Text] [Related]  

  • 20. Polyglutamation of the antifolate anticancer drug N10-propargyl-5,8-dideazafolic acid (CB 3717) in the mouse.
    Manteuffel-Cymborowska M; Sikora E; Grzelakowska-Sztabert B
    Anticancer Res; 1986; 6(4):807-12. PubMed ID: 2875688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.